Speaking of the richest man in Asia, you may think of Li Ka-shing and Jack Ma, but now, the richest man in Asia has finally changed. Zhong Shanshan, chairman of Nongfu Spring, has surpassed Mukesh Ambani, chairman of Indian Reliance Industry Group, to become the new richest man in Asia, only eleven months after he became the richest man in China.

Zhong Shanshan, a native of Zhejiang Province, founded Yangshengtang Co., Ltd. on 1993, and created brands such as Yangshengtang Guibie Pill and Duoer Capsule. 1996, Nongfu Spring Co., Ltd. was established in Hangzhou, and well-known domestic soft drink brands such as Nongfu Spring, Nongfu Orchard and Scream were founded.

In recent years, the richest man in China has been born in the Internet industry, but now Zhong Shanshan has stood out from the traditional consumer industry. How much does Nongfu Spring earn?

When Nongfu Spring decided to make natural water, the monopoly of Wahaha and Robust in the field of pure water began to appear. At that time, the drinking water market accounted for more than 95% of pure water and less than 5% of natural water. China is one of the largest soft drink markets in the world. According to Jost Sullivan's report, the soft drink market in China in 20 19 was 99 14 billion yuan. Due to the acceleration of urbanization, the soft drink market in China will continue to grow. From 20 19 to 2024, the compound annual growth rate is expected to remain at 5.9%. By 2024, the soft drink market in China is expected to reach 6543.8 yuan+323 million yuan.

The company that brings more potential wealth to Zhong Shanshan is Wan Tai Biological Company. The major shareholder of Wan Tai Bio is Yangshengtang. According to the above situation, the actual controller is Zhong Shanshan. According to the prospectus of Wan Tai Bio, Zhong Shanshan holds 78.8 million shares of the company, accounting for about 18.7% of the total shares after issuance.

According to the State Administration of Pharmaceutical Products, the application for registration of bivalent HPV vaccine jointly applied by Wan Tai Canghai, Xiamen University and Wan Tai Bio was approved, which is the first approved HPV vaccine in China, and Canghai, Xiamen Wan Tai, is a subsidiary of Wan Tai Bio. Previously, cervical cancer vaccine products on the market were mainly led by Merck of the United States and GlaxoSmithKline of the United Kingdom. In this context, the approval obtained by Wan Tai Canghai is regarded as breaking the monopoly of imported vaccines. China has also become the third country in the world to independently supply cervical cancer vaccine after Britain and the United States.